Finally, the proteomics results also identified novel potential targets for treating alcohol use disorders, such as gap junction signaling through connexin43, and provide further support for the development of mGluR5 modulators as treatments for substance use and other disorders [25]. This evidence concerns the gene GRM5 and alcohol abuse.